[go: up one dir, main page]

AR132703A1 - TRICYCLIC COMPOUNDS AND THEIR USES - Google Patents

TRICYCLIC COMPOUNDS AND THEIR USES

Info

Publication number
AR132703A1
AR132703A1 ARP240101243A ARP240101243A AR132703A1 AR 132703 A1 AR132703 A1 AR 132703A1 AR P240101243 A ARP240101243 A AR P240101243A AR P240101243 A ARP240101243 A AR P240101243A AR 132703 A1 AR132703 A1 AR 132703A1
Authority
AR
Argentina
Prior art keywords
tricyclic compounds
tricyclic
compounds
preparing
variable
Prior art date
Application number
ARP240101243A
Other languages
Spanish (es)
Inventor
Weihan Zhang
Kun Xiao
Zheng Zhang
Yao Wu
Wei-Guo Su
Original Assignee
Hutchmed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchmed Ltd filed Critical Hutchmed Ltd
Publication of AR132703A1 publication Critical patent/AR132703A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con compuestos tricíclicos de la fórmula (1), composiciones farmacéuticas que los comprenden, métodos de preparación de los mismos y sus usos, en donde cada variable es como se define en la descripción.The present invention relates to tricyclic compounds of the formula (1), pharmaceutical compositions comprising them, methods of preparing them and their uses, wherein each variable is as defined in the description.

ARP240101243A 2023-05-16 2024-05-16 TRICYCLIC COMPOUNDS AND THEIR USES AR132703A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202310552365 2023-05-16
CN202311459371 2023-11-03
CN202410149082 2024-02-01
CN202410567016 2024-05-09

Publications (1)

Publication Number Publication Date
AR132703A1 true AR132703A1 (en) 2025-07-23

Family

ID=93518720

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101243A AR132703A1 (en) 2023-05-16 2024-05-16 TRICYCLIC COMPOUNDS AND THEIR USES

Country Status (4)

Country Link
CN (1) CN121194980A (en)
AR (1) AR132703A1 (en)
TW (1) TW202509040A (en)
WO (1) WO2024235286A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025096738A1 (en) * 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
TW202539672A (en) * 2024-02-06 2025-10-16 大陸商上海齊魯製藥研究中心有限公司 Pyrimidine macrocyclic KRAS inhibitors
WO2025168072A1 (en) * 2024-02-08 2025-08-14 Beigene (Suzhou) Co., Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216762A1 (en) * 2021-04-08 2022-10-13 Genentech, Inc. Oxazepine compounds and uses thereof in the treatment of cancer
WO2023046135A1 (en) * 2021-09-27 2023-03-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
CN116332948A (en) * 2021-12-22 2023-06-27 翰森生物有限责任公司 A nitrogen-containing tetracyclic compound and its preparation method and medicinal use
KR20240163107A (en) * 2022-03-11 2024-11-18 컴쿼트 바이오사이언시즈 인크. Heterocyclic compounds and their uses
CR20240556A (en) * 2022-07-05 2025-01-29 Pfizer Pyrido[4,3-d]pyrimidine Compounds
CA3261298A1 (en) * 2022-07-09 2024-01-18 Blossomhill Therapeutics, Inc. Fused ring kras inhibitors for treating disease
CN119677754A (en) * 2022-08-11 2025-03-21 百济神州(苏州)生物科技有限公司 Heterocyclic compounds, compositions thereof, and methods of treatment using the same
TW202408512A (en) * 2022-08-12 2024-03-01 大陸商正大天晴藥業集團股份有限公司 Tricyclic compounds and medical use thereof
WO2024041621A1 (en) * 2022-08-25 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
CN120077050A (en) * 2022-10-18 2025-05-30 伊迪恩斯股份有限公司 Novel tri-heterocyclic compounds
WO2024083168A1 (en) * 2022-10-19 2024-04-25 Genentech, Inc. Oxazepine compounds comprising a 6-aza moiety and uses thereof
CN120282969A (en) * 2022-11-17 2025-07-08 江苏恒瑞医药股份有限公司 Fused tricyclic compounds, preparation method thereof and application thereof in medicines
WO2024120419A1 (en) * 2022-12-06 2024-06-13 Zai Lab (Shanghai) Co., Ltd. Fused tetracyclic compounds as kras g12d modulators and uses thereof

Also Published As

Publication number Publication date
TW202509040A (en) 2025-03-01
CN121194980A (en) 2025-12-23
WO2024235286A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
AR132703A1 (en) TRICYCLIC COMPOUNDS AND THEIR USES
UY38070A (en) SUBSTITUTE QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS
CL2022002574A1 (en) Amide compounds and uses thereof
CR20220200A (en) BICYCLIC HETEROARYL COMPOUNDS AND USES OF THESE
DOP2011000361A (en) NEW DERIVATIVES OF PYRIMIDINE AND ITS USES IN THE TREATMENT OF CANCER AND OTHER DISEASES
CL2023002274A1 (en) Tricyclic compounds and their uses
CL2025002304A1 (en) Tricyclic bridging carbamoylpyridone compounds and their uses
CO2022016899A2 (en) il-17a modulators
CO2021005509A2 (en) Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CL2022002255A1 (en) Heteroaryl heterocyclic compounds and uses thereof
CO2023000056A2 (en) Amidopyrimidone derivatives
CO2022018636A2 (en) il-17a modulators
MX2023007265A (en) CDK INHIBITORS AND THEIR USE AS PHARMACEUTICAL PRODUCTS.
CL2022002661A1 (en) Benzodiazepine derivatives such as pam from gaba to gamma1
CL2024001635A1 (en) Carbonyl substituted diazaspiro compounds and their use
CL2023000772A1 (en) Heterocyclic heteroaryl compounds and uses thereof
CL2021000381A1 (en) Modified nucleoside phosphoramidites. (application divisional 202000657)
CL2024000313A1 (en) (3-quinolyl)-quinazoline
CL2024000316A1 (en) (3-pyridyl)-quinazoline
ECSP099679A (en) NEW COMPOUNDS AND THEIR USES 707
CL2021000973A1 (en) New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them.
CO2023000858A2 (en) Atr inhibitors and their uses
CL2024002273A1 (en) Pyrazolopyrimidines, compositions comprising them and their uses.
CL2020002058A1 (en) Novel pyridinecarboxamides.
CL2025000551A1 (en) Triazine compounds and their uses

Legal Events

Date Code Title Description
FB Suspension of granting procedure